Multiple Sclerosis Clinical Trial
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Summary
Vaccine responses in patients treated with anti-CD20 antibodies (ocrelizumab and ofatumumab) or S1P receptor modulators (fingolimod and siponimod) were evaluated before and after third SARS-CoV-2 vaccination as part of an ongoing longitudinal study. Total spike protein and spike receptor binding domain (RBD)-specific immunoglobulin G (IgG) responses were measured by Luminex bead-based assay. Spike-specific CD4+ and CD8+ T cell responses were measured by activation-induced marker expression.
Eligibility Criteria
Inclusion Criteria
All Participants:
Aged 18-75 years old MS Patients
Diagnosed with MS based on 2017 McDonald criteria
Exclusion Criteria
All Participants:
Participants with a known history of COVID-19 Healthy Adults
Immunocompromised or on immunosuppressive therapy MS Patients
None specified
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
East Hanover New Jersey, 07936, United States
How clear is this clinincal trial information?